US EditionPublished • loading... • Updated
MDA 2026: Sevasemten Halts Functional Decline in Becker Trial
Summary by Muscular Dystrophy News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Edgewise Therapeutics, a CureDuchenne funded company, announces positive long-term Sevasemten data in Becker muscular dystrophy patients.
Edgewise Therapeutics, a CureDuchenne funded company, today announced positive long-term Sevasemten data that demonstrated sustained functional stabilization in Becker Muscular Dystrophy (BMD) patients through 3.5 years of treatment. This result is in stark contrast to the functional decline expected from BMD natural history data.Today’s result is particularly important for BMD patients, an underserved population, who have no approved treatment …
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
